Lenore Buckley, MD, MPH
Professor of Medicine (Rheumatology, Allergy & Immunology) and of Pediatrics (General Pediatrics)DownloadHi-Res Photo
Cards
Appointments
Rheumatology
Primary
Additional Titles
Professor
Contact Info
Appointments
Rheumatology
Primary
Additional Titles
Professor
Contact Info
Appointments
Rheumatology
Primary
Additional Titles
Professor
Contact Info
About
Titles
Professor of Medicine (Rheumatology, Allergy & Immunology) and of Pediatrics (General Pediatrics)
Professor
Biography
Dr. Buckley is an adult and pediatric rheumatologist with special interests in the treatment of lupus and inflammatory arthritis, glucocorticoid osteoporosis, and the transition of teenagers and young adults with rheumatic diseases to adult care. She is a past member of the FDA Arthritis Advisory Committee and the boards of the American College of Rheumatology and the Arthritis Foundation.
Appointments
Rheumatology
ProfessorPrimary
Other Departments & Organizations
- Antiphospholipid Syndrome Program
- Internal Medicine
- Rheumatology
- Rheumatology, Allergy, & Immunology
- Yale Medicine
- Yale Ventures
Education & Training
- MPH
- Harvard School of Public Health (1993)
- Fellowship
- University of Vermont College of Medicine (1984)
- Residency
- North Carolina Memorial Hospital (1981)
- MD
- University of Rochester (1977)
Research
Overview
Medical Subject Headings (MeSH)
Lupus Erythematosus, Systemic; Osteoporosis, Postmenopausal
Research at a Glance
Publications Timeline
A big-picture view of Lenore Buckley's research output by year.
21Publications
1,935Citations
Publications
2017
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology 2017, 69: 1521-1537. PMID: 28585373, DOI: 10.1002/art.40137.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOral bisphosphonate treatmentGlucocorticoid-induced osteoporosisVitamin DGC treatmentAntifracture medicationsBisphosphonate treatmentFracture riskGC usersHigh-dose GC treatmentLong-term glucocorticoid treatmentLong-term GC treatmentSpecial populationsHarms of interventionsHigh fracture riskLower fracture riskQuality of evidenceGeneral adult populationBisphosphonate regimenGIOP preventionOral bisphosphonatesOsteoporosis medicationsRheumatology guidelinesDenosumab treatmentLifestyle modificationRecommendations Assessment
2009
Reply
Desai S, Solomon D, Abramson S, Buckley L, Crofford L, Cush J, Lovell D, Saag K, Drugs A. Reply. Arthritis & Rheumatism 2009, 61: 285-286. DOI: 10.1002/art.24171.Peer-Reviewed Original ResearchCitations
2001
Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy
Stern A, Riley R, Buckley L. Worsening of Macrophage Activation Syndrome in a Patient with Adult Onset Still’s Disease after Initiation of Etanercept Therapy. JCR Journal Of Clinical Rheumatology 2001, 7: 252-256. PMID: 17039144, DOI: 10.1097/00124743-200108000-00013.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMacrophage activation syndromeActivation syndromeSoluble tumor necrosis factor-alpha receptorEpstein-Barr virus infectionNonsteroidal anti-inflammatory drugsChildhood rheumatic disordersDramatic clinical improvementUse of etanerceptTumor necrosis factor-alpha receptorPeriod of feverAnti-inflammatory drugsEtanercept therapyClinical improvementPulse corticosteroidsLymph nodesParenteral goldRheumatic disordersClinical syndromeHistopathological examinationAdult onsetVirus infectionInfectious processPharmacological agentsBone marrowMononuclear phagocytes
2000
Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition
Buckley L, Sanders K, Shih M, Kallar S, Hampton C. Obstacles to Promotion? Values of Women Faculty about Career Success and Recognition. Academic Medicine 2000, 75: 283-288. PMID: 10724319, DOI: 10.1097/00001888-200003000-00021.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
1999
Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey
Buckley L, Marquez M, Feezor R, Ruffin D, Benson L. Prevention of corticosteroid‐induced osteoporosis: Results of a patient survey. Arthritis & Rheumatism 1999, 42: 1736-1739. PMID: 10446875, DOI: 10.1002/1529-0131(199908)42:8<1736::aid-anr24>3.0.co;2-e.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBone density testingCorticosteroid-induced osteoporosisCorticosteroid treatmentPreventive treatmentLong-term oral corticosteroid treatmentLong-term corticosteroid usersLong-term corticosteroid treatmentDensity testingMean prednisone doseOral corticosteroid treatmentBone density testHormone replacement therapyPrimary care physiciansStandard of careCorticosteroid usersPMP womenPrednisone dosePostmenopausal womenBisphosphonate treatmentCare physiciansOsteoporosis preventionBone lossReplacement therapyCalcium supplementsPatient survey
1998
Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis
Hudson J, Small R, Buckley L. Perceptions of Pharmacists about Adverse Effects of Corticosteroid Therapy: Focus on Osteoporosis. Journal Of The American Pharmacists Association 1998, 38: 710-716. PMID: 9861789, DOI: 10.1016/s1086-5802(16)30392-8.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCorticosteroid therapyPerceptions of pharmacistsCorticosteroid usePostmenopausal womenPremenopausal womenAdverse effectsPatient counselingHigh-dose corticosteroid useWeight gainCorticosteroid-induced osteoporosisHigh-dose corticosteroidsHigh-dose therapyDrug-induced complicationsPrevention of osteoporosisPrednisone useBone densityOsteoporosisHospital pharmacistsMailed surveyTherapyMood changesPharmacistsWomenRespondents' knowledgeCorticosteroidsVariations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.
Buckley L, Marquez M, Hudson J, Downs R, Vacek P, Small R, Poses R. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. The Journal Of Rheumatology 1998, 25: 2195-202. PMID: 9818664.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEstrogen replacement therapyCorticosteroid treatmentPhysician judgmentCorticosteroid usePhysician specialtySide effectsPostmenopausal patientsVitamin DBone lossReplacement therapyCorticosteroid-induced osteoporosisImportance of osteoporosisVitamin D supplementationMajority of patientsRisk of osteoporosisPrimary care physiciansSignificant side effectsHypothetical clinical scenariosImportance of corticosteroidsEfficacy of treatmentD supplementationPostmenopausal womenPremenopausal womenPhysician assessmentCare physicians
1997
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group.
Tuttleman M, Pillemer S, Tilley B, Fowler S, Buckley L, Alarcón G, Trentham D, Neuner R, Clegg D, Leisen J, Heyse S. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. Minocycline in Rheumatoid Arthritis Trial Group. The Journal Of Rheumatology 1997, 24: 1910-5. PMID: 9330931.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPatient global assessmentSF-36Rheumatoid arthritisM-HAQOutcome measuresClinical trialsGlobal assessmentShort Form Health SurveyFunctional health status measuresJoint swelling scoreRA clinical trialsRA outcome measuresHealth Assessment QuestionnaireHealth status instrumentsSF-36 scalesRheumatoid arthritis trialsHealth status measuresMultitrait scaling analysisCross-sectional assessmentCross-sectional analysisMIRA trialStudy patientsRA populationScore correlationsPain itemsImportance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
Buckley L. Importance of guidelines on glucocorticoid‐induced osteoporosis: Comment on the American college of rheumatology recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis & Rheumatism 1997, 40: 1547-1547. PMID: 9259442, DOI: 10.1002/art.1780400829.Peer-Reviewed Original ResearchEffects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
Buckley L, Leib E, Cartularo K, Vacek P, Cooper S. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. The Journal Of Rheumatology 1997, 24: 1489-94. PMID: 9263140.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsBone mineral densityLow-dose methotrexateRheumatoid arthritisLumbar spineFemoral neckDose methotrexateMineral densityBMD of patientsFemoral neck bone mineral densityNeck bone mineral densitySpine bone mineral densityMeasurement of BMDAntirheumatic drug useVitamin D3 supplementationYears of followupGreater bone lossDMARD useD3 supplementationFollowup visitMTX useBone lossPrednisoneSimilar dosePatientsMethotrexate
Clinical Care
Overview
Clinical Specialties
Rheumatology
Board Certifications
Pediatric Rheumatology
- Certification Organization
- AB of Pediatrics
- Latest Certification Date
- 2015
- Original Certification Date
- 2000
Rheumatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1984
Pediatrics
- Certification Organization
- AB of Pediatrics
- Original Certification Date
- 1983
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1981
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- August 29, 2024Source: Everyday Health
Immunosuppressant Drugs for Psoriatic Arthritis
- October 27, 2022
Dr. Linda Bockenstedt and Dr. Richard Bucala Named ACR Masters
- October 22, 2021
Providing Health Care Accessibility for People with Rheumatic Disease in New Haven
- August 07, 2019Source: Medpage Today
With Autoimmunity, Checkpoint Inhibitors Can Be Used
Get In Touch
Contacts
Administrative Support
Locations
Yale Rheumatology
Academic Office
The Anlyan Center
300 Cedar Street, Fl 2nd floor, Ste TAC, Rm S-217
New Haven, CT 06519
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.